(Q46558402)

English

Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study

scientific article published in August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ulrich Keilholz

7

object named as

Ulrich Keilholz

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

4

object named as

Gero Hütter

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

2

object named as

Eckhard Thiel

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

author name string

Jan M Siehl

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

Alexander Schmittel

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

Peter M Deckert

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

Hubert Szelényi

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

104

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

611-617

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of chemotherapy in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II evaluation of adriamycin in human neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose response evaluation of adriamycin in human neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma*

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Adult Soft Tissue Ewing Sarcoma or Primitive Neuroectodermal Tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiotoxicity of adriamycin and related anthracyclines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of liposomal daunorubicin in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21211

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21211

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15968689

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46558402&oldid=2118143397"